Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

New combination therapy eradicates acute lymphoblastic leukemia in children, older adults

In a significant breakthrough, investigators at Weill Cornell Medical College and the University of California, San Francisco, have been able to overcome resistance of a form of leukemia to targeted therapy, demonstrating complete eradication of the cancer in cell and animal studies.

25 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

New study sheds light on origins of myeloid leukemia

A new study by the NYU Cancer Institute, an NCI-designated cancer center, sheds light on the origins of myeloid leukemia, a type of blood cancer that affects children and adults.

13 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

Novel drug holds potential against resistant chronic myeloid leukemia

A study from Tufts Medical Center researchers published today finds that a novel drug shows promise for treating leukemia patients who have few other options because their disease has developed resistance to standard treatment.

12 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011

Scientists identify new treatment target for squamous cell lung cancer

Scientists at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib.

4 Apr 2011

Positive outcomes from imatinib trial in both older and younger patients with CML

While the median age at diagnosis for chronic myeloid leukemia is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML.

31 Mar 2011

Cephalon intends to make takeover bid for ChemGenex

Cephalon, Inc. and ChemGenex Pharmaceuticals Limited today jointly announced that Cephalon's wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd, intends to make a takeover bid for ChemGenex.

29 Mar 2011

Cancer drug Gleevec may hold promise against scleroderma: Study

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.

28 Mar 2011

MolecularMD and ARIAD collaborate to develop and commercialize CML, ALL diagnostic test

ARIAD Pharmaceuticals, Inc. and MolecularMD Corporation today announced an exclusive collaboration agreement in which MolecularMD will develop and commercialize a companion diagnostic test to identify the T315I mutation of the BCR-ABL gene in patients with chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia.

28 Mar 2011

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.

24 Mar 2011

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

New study finds liver instead of the brain as source of Alzheimer’s plaques

Unexpected results from a Scripps Research Institute and ModGene, LLC study could completely alter scientists' ideas about Alzheimer's disease—pointing to the liver instead of the brain as the source of the "amyloid" that deposits as brain plaques associated with this devastating condition. The findings could offer a relatively simple approach for Alzheimer's prevention and treatment.

4 Mar 2011

Researchers identify cell of origin for sarcoma

Researchers at Oregon Health & Science University Doernbecher Children's Hospital have defined the cell of origin for a kind of cancer called sarcoma. In a study published today as the Featured Article in the journal Cancer Cell, they report that childhood and adult sarcomas are linked in their biology, mutations and the cells from which these tumors first start.

16 Feb 2011

Scientists reprogram marrow cells from patient with chronic myeloid leukemia

By coaxing healthy and diseased human bone marrow to become embryonic-like stem cells, a team of Wisconsin scientists has laid the groundwork for observing the onset of the blood cancer leukemia in the laboratory dish.

4 Feb 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA's Office of Orphan Products Development. Melanoma is the most deadly form of skin cancer.

25 Jan 2011

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.

13 Jan 2011